The UK National Competition Authority closes its investigation into an allegedly abusive discount scheme in the pharmaceutical sector (Remicade)

The CMA Remicade decision: discount schemes and abuse of dominance – effects matter!* Summary On 14 March 2019, the UK Competition and Markets Authority (CMA) decided to close its investigation into a discount scheme by Merck Sharp & Dohme Limited (MSD). [1] The CMA concluded that there were no grounds for it to take action, since MSD’s discount strategy was not likely to limit competition in anticipation of the market entry of competitive products. In other words, when analysing a discount, the CMA looked at the likelihood of it having exclusionary effects. Since it found no such likelihood, the investigation was closed. Background In December 2015, the CMA opened a formal investigation, alleging that MSD had abused its dominant position by offering a discount scheme for the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

James Killick, Assimakis Komninos, Strati Sakellariou-Witt, Axel P. Schulz, The UK National Competition Authority closes its investigation into an allegedly abusive discount scheme in the pharmaceutical sector (Remicade), 14 March 2019, e-Competitions Bulletin March 2019, Art. N° 90218

Visites 232

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues